CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells

G. Manic, M. Signore, A. Sistigu, G. Russo, F. Corradi, S. Siteni, M. Musella, S. Vitale, M. L. De Angelis, M. Pallocca, C. A. Amoreo, F. Sperati, S. Di Franco, S. Barresi, E. Policicchio, G. De Luca, F. De Nicola, M. Mottolese, A. Zeuner, M. Fanciulli & 6 others G. Stassi, M. Maugeri-Sacca, M. Baiocchi, M. Tartaglia, I. Vitale, R. De Maria

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies. DESIGN: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents. RESULTS: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients ( approximately 36%). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368. CONCLUSIONS: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.
Original languageEnglish
Pages (from-to)903-917
Number of pages15
JournalGut
Volume67
Issue number5
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Polyploidy
Neoplastic Stem Cells
DNA Replication
Colorectal Neoplasms
Protein Array Analysis
Therapeutics
Cytogenetic Analysis
Neoplasms
Biomarkers
Investigational Drugs
Ataxia Telangiectasia
Mutation
Preclinical Drug Evaluations
Protein-Serine-Threonine Kinases
Mitosis
Phosphorylation
Clinical Trials

Cite this

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. / Manic, G.; Signore, M.; Sistigu, A.; Russo, G.; Corradi, F.; Siteni, S.; Musella, M.; Vitale, S.; Angelis, M. L. De; Pallocca, M.; Amoreo, C. A.; Sperati, F.; Franco, S. Di; Barresi, S.; Policicchio, E.; Luca, G. De; Nicola, F. De; Mottolese, M.; Zeuner, A.; Fanciulli, M.; Stassi, G.; Maugeri-Sacca, M.; Baiocchi, M.; Tartaglia, M.; Vitale, I.; Maria, R. De.

In: Gut, Vol. 67, No. 5, 01.05.2018, p. 903-917.

Research output: Contribution to journalArticle

Manic, G, Signore, M, Sistigu, A, Russo, G, Corradi, F, Siteni, S, Musella, M, Vitale, S, Angelis, MLD, Pallocca, M, Amoreo, CA, Sperati, F, Franco, SD, Barresi, S, Policicchio, E, Luca, GD, Nicola, FD, Mottolese, M, Zeuner, A, Fanciulli, M, Stassi, G, Maugeri-Sacca, M, Baiocchi, M, Tartaglia, M, Vitale, I & Maria, RD 2018, 'CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells', Gut, vol. 67, no. 5, pp. 903-917. https://doi.org/10.1136/gutjnl-2016-312623 [doi]
Manic, G. ; Signore, M. ; Sistigu, A. ; Russo, G. ; Corradi, F. ; Siteni, S. ; Musella, M. ; Vitale, S. ; Angelis, M. L. De ; Pallocca, M. ; Amoreo, C. A. ; Sperati, F. ; Franco, S. Di ; Barresi, S. ; Policicchio, E. ; Luca, G. De ; Nicola, F. De ; Mottolese, M. ; Zeuner, A. ; Fanciulli, M. ; Stassi, G. ; Maugeri-Sacca, M. ; Baiocchi, M. ; Tartaglia, M. ; Vitale, I. ; Maria, R. De. / CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. In: Gut. 2018 ; Vol. 67, No. 5. pp. 903-917.
@article{519b439071fa42518c2286062bc732dc,
title = "CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells",
abstract = "OBJECTIVE: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies. DESIGN: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents. RESULTS: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients ( approximately 36{\%}). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368. CONCLUSIONS: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.",
author = "G. Manic and M. Signore and A. Sistigu and G. Russo and F. Corradi and S. Siteni and M. Musella and S. Vitale and Angelis, {M. L. De} and M. Pallocca and Amoreo, {C. A.} and F. Sperati and Franco, {S. Di} and S. Barresi and E. Policicchio and Luca, {G. De} and Nicola, {F. De} and M. Mottolese and A. Zeuner and M. Fanciulli and G. Stassi and M. Maugeri-Sacca and M. Baiocchi and M. Tartaglia and I. Vitale and Maria, {R. De}",
note = "LR: 20181113; CI: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.; JID: 2985108R; 0 (Antineoplastic Agents); 0 (Pyrazines); 0 (Pyrazoles); 0 (Tumor Suppressor Protein p53); 0 (prexasertib); EC 2.7.11.1 (CHEK1 protein, human); EC 2.7.11.1 (Checkpoint Kinase 1); OTO: NOTNLM; 2016/07/15 00:00 [received]; 2017/02/03 00:00 [revised]; 2017/02/28 00:00 [accepted]; 2017/04/09 06:00 [pubmed]; 2018/06/19 06:00 [medline]; 2017/04/09 06:00 [entrez]; ppublish",
year = "2018",
month = "5",
day = "1",
doi = "10.1136/gutjnl-2016-312623 [doi]",
language = "English",
volume = "67",
pages = "903--917",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells

AU - Manic, G.

AU - Signore, M.

AU - Sistigu, A.

AU - Russo, G.

AU - Corradi, F.

AU - Siteni, S.

AU - Musella, M.

AU - Vitale, S.

AU - Angelis, M. L. De

AU - Pallocca, M.

AU - Amoreo, C. A.

AU - Sperati, F.

AU - Franco, S. Di

AU - Barresi, S.

AU - Policicchio, E.

AU - Luca, G. De

AU - Nicola, F. De

AU - Mottolese, M.

AU - Zeuner, A.

AU - Fanciulli, M.

AU - Stassi, G.

AU - Maugeri-Sacca, M.

AU - Baiocchi, M.

AU - Tartaglia, M.

AU - Vitale, I.

AU - Maria, R. De

N1 - LR: 20181113; CI: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.; JID: 2985108R; 0 (Antineoplastic Agents); 0 (Pyrazines); 0 (Pyrazoles); 0 (Tumor Suppressor Protein p53); 0 (prexasertib); EC 2.7.11.1 (CHEK1 protein, human); EC 2.7.11.1 (Checkpoint Kinase 1); OTO: NOTNLM; 2016/07/15 00:00 [received]; 2017/02/03 00:00 [revised]; 2017/02/28 00:00 [accepted]; 2017/04/09 06:00 [pubmed]; 2018/06/19 06:00 [medline]; 2017/04/09 06:00 [entrez]; ppublish

PY - 2018/5/1

Y1 - 2018/5/1

N2 - OBJECTIVE: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies. DESIGN: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents. RESULTS: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients ( approximately 36%). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368. CONCLUSIONS: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.

AB - OBJECTIVE: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies. DESIGN: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents. RESULTS: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients ( approximately 36%). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368. CONCLUSIONS: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.

U2 - 10.1136/gutjnl-2016-312623 [doi]

DO - 10.1136/gutjnl-2016-312623 [doi]

M3 - Article

VL - 67

SP - 903

EP - 917

JO - Gut

JF - Gut

SN - 0017-5749

IS - 5

ER -